Testosterone and human behavior: the role of individual and contextual variables.

J. Carré,J. Archer

DOI: https://doi.org/10.1016/j.copsyc.2017.03.021

IF: 6.813

2018-02-01

Current Opinion in Psychology

Abstract:

What problem does this paper attempt to address?

Efficacy and Tolerability of Adding Coenzyme A 400 U/d Capsule to Stable Statin Therapy for the Treatment of Patients with Mixed Dyslipidemia: an 8-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study

Jiangtao Lai,Bifeng Wu,Tianming Xuan,Zhong Liu,Junzhu Chen

DOI: https://doi.org/10.1186/1476-511x-13-1

2014-01-01

Lipids in Health and Disease

Abstract:Background Patients with mixed hyperlipidemia usually are in need of combination therapy to achieve low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) target values for reduction of cardiovascular risk. This study investigated the efficacy and safety of adding a new hypolipidemic agent, coenzyme A (CoA) to stable statin therapy in patients with mixed hyperlipidemia. Methods In this multi-center, 8-week, double-blind study, adults who had received ≥8 weeks of stable statin therapy and had hypertriglyceridemia (TG level at 2.3-6.5 mmol/L) were randomized to receive CoA 400 U/d or placebo plus stable dosage of statin. Efficacy was assessed by the changes in the levels and patterns of lipoproteins. Tolerability was assessed by the incidence and severity of adverse events (AEs). Results A total of 304 patients with mixed hyperlipidemia were randomized to receive CoA 400 U/d plus statin or placebo plus statin (n = 152, each group). After treatment for 8 weeks, the mean percent change in TG was significantly greater with CoA plus statin compared with placebo plus statin (-25.9% vs -4.9%, respectively; p = 0.0003). CoA plus statin was associated with significant reductions in TC (-9.1% vs -3.1%; p = 0.0033), LDL-C (-9.9% vs 0.1%; p = 0.003), and non- high-density lipoprotein cholesterol (-13.5% vs -5.7%; p = 0.0039). There was no significant difference in the frequency of AEs between groups. No serious AEs were considered treatment related. Conclusions In these adult patients with persistent hypertriglyceridemia, CoA plus statin therapy improved TG and other lipoprotein parameters to a greater extent than statin alone and has no obviously adverse effect. Trial registration Current Controlled Trials ClinicalTrials.gov ID NCT01928342 .
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update

Ozge Telci Caklili,Manfredi Rizzo,Mustafa Cesur

DOI: https://doi.org/10.2174/0115701611290763240126045433

2024-02-07

Current Vascular Pharmacology

Abstract:Abstract: Statins play a significant role in the prevention of cardiovascular (CV) diseases (CVDs); however, non-adherence with statin treatment or statin intolerance (mainly attributed to muscleassociated side effects) is not uncommon. New agents such as bempedoic acid (BA) can provide more treatment options. BA is administered orally, once daily, at a dose of 180 mg in current clinical practice. It can decrease circulating low-density lipoprotein cholesterol (LDL-C) levels by nearly 30% as monotherapy or by 20% as an add-on to statins. CV outcome studies have shown that BA decreases major adverse CV event risk in patients with established CVD or high CV risk by 13%. When patients with high CV risk were analyzed alone, the risk reduction was 30%. Its side effects include a rise in serum uric acid levels and liver enzyme activity, whereas it does not increase diabetes risk as statins do. BA can be used as adjunctive therapy to statins in patients at high CV risk in whom lipid targets cannot be achieved or as an alternative to statins in patients with statin intolerance.

pharmacology & pharmacy,peripheral vascular disease
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs

A Michael Lincoff,Kausik K Ray,William J Sasiela,Tariq Haddad,Stephen J Nicholls,Na Li,Leslie Cho,Denise Mason,Peter Libby,Shaun G Goodman,Steven E Nissen

DOI: https://doi.org/10.1016/j.jacc.2024.04.048

2024-07-09

Abstract:Background: In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events. Objectives: This study sought to determine whether the relationship between LDL-C lowering and cardiovascular benefit achieved with bempedoic acid resembles that observed with statins when standardized per unit change in LDL-C. Methods: To compare the treatment effect of bempedoic acid with statins, the methodology of the Cholesterol Treatment Trialists' Collaboration (CTTC) was applied to outcomes among the 13,970 patients enrolled in the CLEAR Outcomes trial. The CTTC endpoint of "major vascular event" was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal stroke, or coronary revascularization. HRs for CTTC-defined endpoints were normalized to 1 mmol/L differences in LDL-C levels between bempedoic acid and placebo groups. Results: A first major vascular event occurred in 703 (10.1%) patients in the bempedoic acid group and 816 (11.7%) patients in the placebo group (HR: 0.85; 95% CI: 0.77-0.94). When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis. Normalized risk reductions were similar for bempedoic acid and statins for the endpoints of major coronary events, nonfatal myocardial infarction, and coronary revascularization. Conclusions: Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406).
Efficacy of Statin Monotherapy or in Combination with Coenzyme A Capsule in Patients with Metabolic Syndrome and Mixed Dyslipidemia

Jiangtao Lai,Bifeng Wu,Tianming Xuan,Shudong Xia,Zhong Liu,Junzhu Chen

DOI: https://doi.org/10.14740/jocmr2124w

2015-01-01

Journal of Clinical Medicine Research

Abstract:BACKGROUND:Patients with metabolic syndrome are at increased risk for cardiovascular disease. Combination lipid-lowering therapy is often needed in patients with metabolic syndrome and mixed dyslipidemia. The aim of this study was to compare the effect of statin combined with a new hypolipidemic agent, coenzyme A (CoA) with moderate-dose statin monotherapy in subjects with metabolic syndrome and mixed dyslipidemia by evaluating data from a subgroup of patients with metabolic syndrome and mixed dyslipidemia from a previously conducted randomized study.METHODS:In the present post hoc analysis, 212 patients were included, receiving statin monotherapy (n = 94) or statin combined with CoA 400 U/day (n = 118) for 8 weeks. The lipoprotein profile was determined at baseline and week 8 visits. Attainment of low-density lipoprotein-cholesterol (LDL-C) < 100 mg/dL, non-high-density lipoprotein-cholesterol (HDL-C) < 130 mg/dL, and the combined goal of these two parameters was also evaluated.RESULTS:The mean percent change was more prominent with CoA plus statin compared with placebo plus statin in triglyceride (TG) (-32.5% vs. -8.7%, respectively; P = 0.0002), total cholesterol (-9.6% vs. -3.6%, P = 0.013), LDL-C (-7.5% vs. 2.1%, P = 0.033), and non-HDL-C (-14.3% vs. -6.4%, P = 0.011). Treatment with CoA plus statin resulted in larger percentages of participants attaining lipid goals for LDL-C (70.3% vs. 56.4%, P = 0.044), non-HDL-C (60.2% vs. 45.7%, P = 0.039), and the combined goal of LDL-C and non-HDL-C (57.6% vs. 42.6%, P = 0.038) than statin monotherapy.CONCLUSION:These results demonstrate that CoA plus statin therapy was more effective in improving lipoprotein parameters than statin alone in patients with metabolic syndrome and mixed hyperlipidemia.
The proteins and the mechanisms of apoptosis: a mini-review of the fundamentals.

Papaliagkas,A. Anogianaki,G. Anogianakis,G. Ilonidis

2007-07-01

Hippokratia

Abstract:Apoptosis or programmed cell death is a physiological mechanism, characterized by specific morphological and biochemical changes such as cell shrinkage, chromatin condensation, protein cleavage, DNA breakdown and phagocytosis. Apoptosis is a significant contributor to the morphologic and functional development of multicellular organisms. It is also involved in the pathogenesis of several diseases including degenerative diseases of the central nervous system (CNS) like Alzheimer's disease or Parkinson's disease, cancer and immune system dysfunction. There are many factors, mainly proteins, which are involved in the activation, regulation and execution of related events. A fairly detailed outline of apoptotic mechanisms has also started to emerge and to be verified. In this short, focused mini-review, we attempt to outline current evidence regarding the mechanisms and the regulation of apoptosis.
Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Shui-ping Zhao,Fang Wang,Yangyang Dai,Ling Lin,Qiguang Tong,Yuhua Liao,Yuehui Yin,Guang Wang,Yafei Yan,Xiaodong Li,Dao Wen Wang,Ping Wei,Xingbo Cheng,Qiang Xie,Yuemin Sun,Guosheng Fu,Hongman Huang,Yugang Dong,Jianxiong Liu,Jianling Yan,Li Yan,Shiwei Cui,Xuebo Liu,Zhaoping Li,Hong Chen,Taohong Hu,Hui Gong

DOI: https://doi.org/10.1016/j.ijcard.2016.06.234

IF: 4.039

2016-01-01

International Journal of Cardiology

Abstract:Background: Since the withdrawal of cerivastatin, statin-fibrate combination therapy has been questioned in China due to safety concern. The objective of this study was to evaluate the efficacy and safety profile of fenofibrate as an add-on in patients with dyslipidemia despite receiving statin therapy.Methods: This was a prospective, multi-center, single-arm, open-label study conducted in Chinese dyslipidemia patients with high CV risk. Fenofibrate (200 mg daily) was added to the existing statin treatment for 8 weeks. Lipid profile and safety parameters were measured and compared between baseline and after the treatment. Five hundred and six subjects were enrolled from 28 sites from 14 cities nationwide across China.Results: After 8 weeks of fenofibrate treatment, the mean blood triglyceride level decreased to 1.77 mmol/L (38.1% reduction vs. 3.00 mmol/L at the baseline; p < 0.01). Mean high-density lipoprotein cholesterol (high density lipoprotein cholesterol) was increased to 1.22 mmol/L (by 17.4% from 1.07 mmol/L at the baseline; p < 0.01). No case of severe muscle damage (defined as elevated creatine kinase over 5 times of upper limit of normal (ULN) or rhabdomyolysis was observed.Conclusion: In statin-treated patients with high CV risk who had elevated triglyceride, adding fenofibrate could improve lipid profile with acceptable safety profiles. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials

P. Barton Duell,Maciej Banach,Alberico L. Catapano,Ulrich Laufs,G. B. John Mancini,Kausik K. Ray,Christine Broestl,Yang Zhang,Lei Lei,Anne C. Goldberg

DOI: https://doi.org/10.1016/j.jacl.2023.12.005

IF: 5.365

2024-01-13

Journal of Clinical Lipidology

Abstract:Background Patients with heterozygous familial hypercholesterolemia (HeFH) often cannot reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals despite multidrug therapy. Objective To evaluate the efficacy and safety of bempedoic acid as an add-on therapy for lowering LDL-C in patients with HeFH. Methods Pooled data from two 52-week phase 3 clinical trials of patients with atherosclerotic cardiovascular disease and/or HeFH receiving maximally tolerated statin therapy (randomized 2:1 to bempedoic acid or placebo) were analyzed by HeFH status. Endpoints included changes from baseline to week 12 (and up to week 52) in LDL-C and other lipid parameters, achievement of LDL-C goals, and safety. Results A total of 217 (bempedoic acid, 146; placebo, 71) patients with HeFH and 2,792 (bempedoic acid, 1,864; placebo, 928) without HeFH were included (mean baseline LDL-C, 172.8 mg/dL and 102.6 mg/dL, respectively). Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status (with HeFH, −21.2%; without HeFH, −18.2% [both P <0.0001]). Bempedoic acid significantly reduced other lipid parameters and high-sensitivity C-reactive protein vs. placebo regardless of HeFH status (all P ≤0.01). Among patients with HeFH treated with bempedoic acid, 32% and 27% achieved LDL-C <100 mg/dL at weeks 12 and 52, respectively. Overall treatment-emergent adverse event incidence was comparable across all four groups (74.7–77.5%). Conclusion Bempedoic acid significantly lowered LDL-C levels vs. placebo and was generally well tolerated in all patients, with no new safety findings in patients with HeFH, despite more intensive lipid-lowering therapy in patients with vs. without HeFH.

pharmacology & pharmacy
Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials

Ovidio De Filippo,Fabrizio D’Ascenzo,Mario Iannaccone,Maurizio Bertaina,Attilio Leone,Irene Borzillo,Emanuele Ravetti,Andrea Solano,Ilaria Pagliassotto,Marco Nebiolo,Francesco Bruno,Federico Giacobbe,Saverio Muscoli,Silvia Monticone,Maria Felice Brizzi,Giuseppe Biondi Zoccai,Gaetano Maria De Ferrari

DOI: https://doi.org/10.1186/s12933-023-02022-z

IF: 8.949

2023-11-28

Cardiovascular Diabetology

Abstract:Abstract Background and aims Bempedoic Acid (BA) is a novel Lipid-Lowering Therapy (LLT). We performed a systematic review and meta-analysis to assess the efficacy and safety of BA in patients with hypercholesterolemia. Methods PubMed, Scopus, and Cochrane library databases were searched for randomised controlled trials evaluating the efficacy and/or safety of BA compared with placebo. Trials investigating dosages other than 180 mg/die were excluded. Major adverse cardiovascular events (MACE) were the primary efficacy endpoint. LDL-cholesterol reduction was the primary laboratory endpoint. Pre-specified safety endpoints included muscle-related adverse events, new-onset diabetes, and gout. The protocol was registered on PROSPERO (temporary ID:399,867). Results Study search identified 275 deduplicated results. 11 studies, encompassing 18,315 patients (9854 on BA vs 8461 on placebo/no treatment) were included. BA was associated with a reduced risk of MACE (OR 0.86, 95% CI 0.79–0.95), myocardial infarction (OR 0.76, 95% CI 0.64–0.88) and unstable angina (OR 0.69, 95% CI 0.54–0.88) compared to control, over a median follow up of 87 (15–162) weeks. BA was associated with a reduction of LDL-Cholesterol (mean difference [MD]–22.42,95% CI − 24.02% to − 20.82%), total cholesterol (− 16.50%,95% − 19.21% to − 13.79%), Apo-B lipoprotein (− 19.55%, − 22.68% to − 16.42%) and high-sensitivity CRP (− 27.83%, − 31.71% to − 23.96%) at 12 weeks. BA was associated with a higher risk of gout (OR 1.55, 95% CI 1.27–1.90) as compared with placebo. Efficacy on laboratory endpoints was confirmed, with a variable extent, across patients on statin or ezetimibe background therapy. Conclusions The improved cholesterol control achieved with BA translates into a reduced risk of MACE, including myocardial infarction and coronary revascularisation. The drug has a satisfactory safety profile except for an increased risk of gout.

cardiac & cardiovascular systems,endocrinology & metabolism
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis

D Mutschlechner,M Tscharre,K Huber,T Gremmel

DOI: https://doi.org/10.1093/eurheartj/ehae666.2854

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Aims Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular mortality and morbidity. Bempedoic acid represents a promising novel lipid modifying agent for patients who cannot reach guideline recommended LDL-C goals or statin-intolerant patients, but data on safety and cardiovascular outcomes are limited. We therefore aimed to systematically review randomized controlled trials investigating bempedoic acid versus placebo in patients with hyperlipidemia. Methods A systematic search on the databases PubMed, Web of Science, and Embase until 20 March 2023 was performed. All randomized trials comparing bempedoic acid (180 mg daily) with placebo in patients with an indication for lipid-lowering therapy were included. As primary endpoint we analysed three-point major adverse cardiovascular events (MACE) consisting of cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal stroke. The analysis was carried out using the odds ratio as the outcome measure. Due to the expected heterogeneity across studies a random-effects model was fitted to the data. Results Out of 258 manuscripts, 10 manuscripts fulfilled the inclusion criteria. In total, these trials included 18,200 patients (9,765 on bempedoic acid, 8,435 on placebo). Bempedoic acid significantly reduced MACE compared to placebo (OR 0.84 [95% CI 0.76-0.96]; p<0.001; I2=0%). The endpoint reduction was driven by a lower rate of non-fatal MI, whereas bempedoic acid had no significant effect on stroke (OR 0.86 [95% CI 0.69-1.08]; p=0.20, I2=0%) and all-cause mortality (OR 1.19 [95% CI 0.73-1.93]; p=0.49; I2=18%). Conclusion Bempedoic acid reduced non-fatal MI in patients with hyperlipidemia, whereas it had no significant effect on stroke and all-cause mortality.Figure.Forest plot for three-point MACE

cardiac & cardiovascular systems
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Alessandro Di Minno,Roberta Lupoli,Ilenia Calcaterra,Paolo Poggio,Francesco Forte,Gaia Spadarella,Pasquale Ambrosino,Gabriella Iannuzzo,Matteo Nicola Dario Di Minno

DOI: https://doi.org/10.1161/JAHA.119.016262

IF: 6.106

2020-07-23

Journal of the American Heart Association

Abstract:Background Bempedoic acid (BA) is a novel lipid‐lowering drug. We performed a systematic review and meta‐analysis on efficacy and safety of BA compared with standard treatment in patients with hypercholesterolemia. Methods and Results Studies were systematically searched in the PubMed, Web of Science, Scopus, and EMBASE databases. Efficacy outcome was represented by percentage changes (mean difference [MD] with pertinent 95% CIs) in total cholesterol, low‐density lipoprotein cholesterol, triglycerides, high‐density lipoprotein cholesterol, apolipoprotein B, non–high‐density lipoprotein cholesterol, and hs‐CRP (high‐sensitivity C‐reactive protein) in BA patients and controls. Seven studies were included (2767 BA‐treated patients and 1469 controls), showing a more significant reduction in low‐density lipoprotein cholesterol (MD, −17.5%; 95% CI, −22.9% to −12.0%), total cholesterol (MD, −10.9%; 95% CI, −13.3% to −8.5%), non–high‐density lipoprotein cholesterol (MD, −12.3%; 95% CI, −15.3% to −9.20%), apolipoprotein B (MD, −10.6%; 95% CI, −13.2% to −8.02%), and hs‐CRP (MD, −13.2%; 95% CI, −16.7% to −9.79%) in BA‐treated patients compared with controls. Results were confirmed when separately analyzing studies on patients with high cardiovascular risk, studies on statin‐intolerant patients, and studies on patients with hypercholesterolemia on maximally tolerated lipid‐lowering therapy. BA‐treated subjects reported a higher rate of treatment discontinuation caused by adverse effects, of gout flare, and of increase in uric acid compared with controls. On the other hand, BA‐treated patients showed a lower incidence of new‐onset diabetes mellitus than controls. Conclusions BA is associated with a significant reduction in low‐density lipoprotein cholesterol, total cholesterol, non–high‐density lipoprotein cholesterol, apolipoprotein B, and hs‐CRP compared with standard treatment. Documented efficacy is accompanied by an acceptable safety profile. Nonstandard Abbreviations and Acronyms Apo Bapolipoprotein B BA bempedoic acid HDL‐C high‐density lipoprotein cholesterol hs‐CRP high‐sensitivity C‐reactive protein LDL‐C low‐density lipoprotein cholesterol MD mean difference OR odds ratio RCT randomized controlled trial TC total cholesterol Clinical Perspective What Is New? Bempedoic acid is a safe and effective lipid‐lowering agent for the treatment of hypercholesterolemia, associated with a significant reduction in total cholesterol, low‐density lipoprotein cholesterol, non–high‐density lipoprotein cholesterol, apolipoprotein B, and hs‐CRP (high‐sensitivity C‐reactive protein). Bempedoic acid is a valuable treatment option (1) for patients with statin intolerance, not able to receive an adequate lipid‐lowering treatment; and (2) for patients with high cardiovascular risk, not reaching desired target of low‐density lipoprotein cholesterol despite a maximally tolerated lipid‐lowering treatment, including both statin and ezetimibe. What Are the Clinical Implications? Although data are currently lacking, a treatment with bempedoic acid on top of maximally tolerated lipid‐lowering treatment might reduce the need of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors. Several studies emphasize the role of high levels of low‐density lipoprotein cholesterol (LDL‐C) as the main causative factor in atherosclerosis development. 1 , 2 Among patients with hypercholesterolemia, those with high levels of LDL‐C exhibit increased prevalence of subclinical atherosclerosis and a more rapid atherosclerosis progression, thus leading to a significantly higher cardiovascular risk 1 and related dis -Abstract Truncated-

cardiac & cardiovascular systems
Efficacy and Safety of Hybutimibe in Combination with Atorvastatin for Treatment of Hypercholesteremia among Patients with Atherosclerotic Cardiovascular Disease Risk Equivalent: A Multicenter, Randomized, Double-Blinded Phase III Study.

Litong Qi,Jiyan Chen,Xiaodong Li,Xiaoyong Qi,Chunhua Ding,Xiaoping Chen,Xiang Gu,Wenliang Xiao,Shuiping Zhao,Yugang Dong,Mingqi Zheng,Kai Huang,Liangqiu Tang,Xiaomei Guo,Fang Wang,Guosheng Fu,Junxia Li,Yong Huo

DOI: https://doi.org/10.3389/fcvm.2022.888604

IF: 3.6

2022-01-01

Frontiers in Cardiovascular Medicine

Abstract:BackgroundTo evaluate the safety and efficacy of hybutimibe plus atorvastatin for lipid control in hypercholesterolemia patients with atherosclerotic cardiovascular disease risk equivalent.MethodsIn this double-blind phase III study, we 1:1 randomly assigned 255 hypercholesterolemia patients with atherosclerotic cardiovascular disease to receive hybutimibe plus atorvastatin or placebo plus atorvastatin. The primary endpoint was the rate of change of plasma low-density lipoprotein-cholesterol (LDL-C) level at 12 weeks from baseline. The secondary endpoints were plasma total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), non-HDL-C, apoprotein (Apo) B, and 2-, 4-, 8-, and 12-week Apo A1 levels change rate and rates of change of plasma LDL-C levels at 2, 4, and 8 weeks from baseline.ResultsFrom April 2016 to January 2018, 128 in the hybutimibe plus atorvastatin group and 125 in the atorvastatin group were included in modified intention-to-treat (mITT) analysis. After 12 weeks of treatment, LDL-C level changed from 2.61 mmol/L (±0.30) at baseline to 2.18 mmol/L (±0.45) in the hybutimibe plus atorvastatin group and from 2.58 (±0.31) mmol/L to 2.40 (± 0.46) mmol/L in the atorvastatin group (P < 0.0001), in mITT. The change rate in the hybutimibe plus atorvastatin group was significantly higher than that in the atorvastatin group (P < 0.0001); the estimated mean rates of change were −16.39 (95% confidence interval: −19.04, −13.74) and −6.75 (−9.48, −4.02), respectively. Consistently, in per-protocol set (PPS) analysis, the rate of change of LDL-C in the hybutimibe plus atorvastatin group was significantly higher than that in atorvastatin group. Significant decreases in the change rates of non-HDL-C, TC, and Apo B at 2, 4, 8, and 12 weeks (all P < 0.05) were observed for hybutimibe plus atorvastatin, while the differences were not significant for HDL-C, TG, and Apo-A1 (all P > 0.05). During the study period, no additional side effects were reported.ConclusionsHybutimibe combined with atorvastatin resulted in significant improvements in LDL-C, non-HDL-C, TC, and Apo B compared with atorvastatin alone. The safety and tolerability were also acceptable, although additional benefits of hybutimibe plus atorvastatin were not observed compared with atorvastatin alone in HDL-C, TG, and Apo-A1.
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia

Angela Pirillo,Alberico L Catapano

DOI: https://doi.org/10.1097/MED.0000000000000706

2022-04-01

Abstract:Purpose of review: A number of new cholesterol-lowering drugs have been recently developed and approved, enriching the pharmacological armamentarium beyond and above statins. Ezetimibe, available since two decades, and bempedoic acid, a new drug inhibiting the same biosynthetic pathway targeted by statins but at an early step, represent valuable tools for the treatment of hypercholesterolemia, particularly in specific groups of patients. Recent findings: Bempedoic acid, either alone or in combination with ezetimibe, appears to reduce significantly LDL-C levels, an effect that has been observed also in patients with statin intolerance. A Mendelian randomization study has anticipated a protective cardiovascular effect of bempedoic acid; a randomized clinical trial is currently assessing whether the pharmacological control of hypercholesterolemia with bempedoic acid translates into a clinical benefit. Bempedoic acid, as well as ezetimibe, does not appear to induce adverse events in muscles; moreover, whereas statins are associated with a modest, although significant, increased risk of new-onset diabetes, bempedoic acid does not, at least based on the available evidence. Summary: On the basis of available data, and while awaiting the results of the outcome trial, bempedoic acid appears to represent a valuable approach for the treatment of hypercholesterolemia, either alone or in combination in ezetimibe.
Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review

Yi Li,Hongyu Gao,Jinghui Zhao,Liqing Ma,Dan Hu

DOI: https://doi.org/10.1371/journal.pone.0297854

IF: 3.7

2024-01-27

PLoS ONE

Abstract:Bempedoic acid, an innovative oral medication, has garnered significant interest in recent times due to its potential as a therapeutic intervention for hypercholesterolemia. Nonetheless, the outcomes of the initial investigations might have been more definitive and coherent. Our objective was to perform a quantitative meta-analysis in order to evaluate bempedoic acid's safety and effectiveness. A search was conducted on ClinicalTrials.gov, and PubMed from the time of inception until September 28, 2023. Randomized controlled trials comparing the safety and efficacy of bempedoic acid among patients with statin intolerance and those without were included in our analysis. The trial outcomes were summarized using a random effects model and were provided as mean differences or odds ratios (ORs) with a confidence interval of 95%. Additionally, trial heterogeneity and the possibility of bias were evaluated and investigated. Bempedoic acid treatment reduced low-density lipoprotein cholesterol levels more than placebo (mean difference -2.97%, 95% CI -5.89% to -0.05%), according to a pooled analysis of 16 eligible trials. The risk of death (OR 1.18, 95% CI 0.70 to 1.98) and muscle-associated occurrences (OR 1.00, 95% CI 0.77 to 1.31) was not impacted by bempedoic acid. In contrast, discontinuation of treatment was more frequently caused by adverse events in the bempedoic acid group (OR 1.13, 95% CI 1.01 to 1.27). In patients with statin intolerance as well as those without, bempedoic acid is a safe and efficacious lipid-lowering agent, according to findings from randomized controlled trials.

multidisciplinary sciences
A Systematic Review and Meta-Analysis on the Role of Bempedoic Acid in Cardiovascular Outcomes for Patients With Statin Intolerance

Mohamed H Serour,Musab Egaimi,Zahid Khan

DOI: https://doi.org/10.7759/cureus.61572

2024-06-03

Cureus

Abstract:Atherosclerosis, a multifaceted pathogenic process affecting the arteries and aorta, poses a significant threat because of its potential to impede or entirely obstruct blood flow by narrowing blood vessels. This intricate progression involves various factors such as dyslipidemia, immunological responses, inflammation, and endothelial dysfunction. The initial phase manifests as the formation of fatty streaks, considered a pivotal hallmark in the inception of atherosclerotic plaques, a process that can commence as early as childhood. Over time, this process evolves, characterized by the thickening of the arterial inner layer (intima) and accumulation of lipid-laden macrophages, commonly known as foam cells, along with the buildup of the extracellular matrix. Subsequent stages witness the proliferation and aggregation of smooth muscle cells, culminating in the formation of atheroma plaques. As these lesions progress, apoptosis can occur in the deeper layers, further recruiting macrophages, which may undergo calcification and transform into atherosclerotic plaques. Notably, mechanisms such as arterial remodeling and intraplaque hemorrhage also contribute significantly to the progression of atherosclerotic cardiovascular disease, although these facets fall beyond the scope of this article. This study aimed to systematically review and conduct a meta-analysis of randomized controlled trials investigating the efficacy and safety of bempedoic acid in statin-intolerant patients with hyperlipidemia and to provide conclusions and recommendations accordingly. A systematic search of databases, such as PubMed, Web of Science, and Embase, will be performed. Only randomized trials will be included comparing bempedoic acid with placebo in statin-intolerant patients. This study aimed to provide a comprehensive understanding of the role of bempedoic acid in managing hyperlipidemia in statin-intolerant patients. In primary prevention, for patients unable to tolerate recommended statins, bempedoic acid was associated with a significant reduction in major adverse cardiovascular events (MACE) as the primary endpoint.
Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)

Giuseppe Marazzi,Giuseppe Campolongo,Francesco Pelliccia,Silvia Quattrino,Cristiana Vitale,Luca Cacciotti,Rosalba Massaro,Maurizio Volterrani,Giuseppe Rosano

DOI: https://doi.org/10.1016/j.amjcard.2017.06.015

2017-09-15

Abstract:Low-density lipoprotein cholesterol (LDL-C) reduction is associated with a significant decrease in mortality, and statins represent the most effective drugs to achieve this. However, side effects of statins are very common and may lead to treatment discontinuation. Nutraceuticals are a combination of natural components that have shown efficacy in lowering LDL-C concentration when used alone or in association with other agents in patients who are intolerant to high-dose statins. Our aim was to compare the efficacy and tolerability of low-dose statin (LDS) therapy versus combined therapy of LDS plus a nutraceutical combination containing red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin (Armolipid Plus) in high-risk patients. We performed a randomized (1:1), prospective, parallel group, single-blind trial in which participants had coronary artery disease (n = 100), had undergone percutaneous coronary intervention in the preceding 12 months, were high-dose statin intolerant, and did not achieve ≥50% reduction in LDL-C with LDS treatment alone. After 3 months, patients in the LDS + Armolipid Plus (n = 50) group presented with a significantly greater reduction of LDL-C and total cholesterol (p <0.0001), and 70% of patients in this group achieved the therapeutic target (LDL-C <70 mg/dl), whereas patients in the LDS group did not. Six patients (3 from each group) dropped out due to myalgia. In conclusion, in patients with coronary artery disease and high-dose statin intolerance, the combination of LDS and nutraceuticals represents a valuable therapeutic option.
Combined brachytherapy and external radiotherapy for carcinoma of the prostate. Experience and results.

V. Ciarniello,G. Palazzoni

Abstract:
Chronic light damage to the macula of an endoscopist.

H. Kaiser,J. Flammer,G. Miller

DOI: https://doi.org/10.1016/S0016-5107(92)70455-6

IF: 10.396

1992-05-01

Gastrointestinal Endoscopy

Abstract:
Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis

Walter Masson,Martín Lobo,Augusto Lavalle-Cobo,Gerardo Masson,Graciela Molinero

DOI: https://doi.org/10.1016/j.diabres.2020.108369

Abstract:Introduction: Bempedoic acid is a new agent that reduces low-density lipoprotein cholesterol. Since inhibits cholesterol synthesis through a different mechanism than statins, the adverse effects related to it may also be different. Therefore, the objective of the present meta-analysis was to evaluate the effect of bempedoic acid on new onset or worsening diabetes. Methods: We performed a meta-analysis including randomized trials of bempedoic acid therapy, reporting new onset or worsening diabetes with a minimum of 4 weeks of follow-up. The fixed-effects model was performed. This meta-analysis was performed according to PRISMA guidelines. Results: Five eligible trials of bempedoic acid, including 3629 patients, were identified and considered eligible for the analyses. A total of 2419 subjects were allocated to receive bempedoic acid while 1210 subjects were allocated to the respective control arms. Bempedoic acid therapy is associated with a significant reduction in new onset or worsening diabetes [Odds Ratio: 0.66, 95% confidence interval: 0.48-0.90; I2: 0%]. Conclusion: This data suggests that the use of bempedoic acid significantly reduces the new onset or worsening diabetes risk. This finding should be confirmed with future studies.
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome

Gianni Biolo,Pierandrea Vinci,Alessandro Mangogna,Matteo Landolfo,Paolo Schincariol,Nicola Fiotti,Filippo Mearelli,Filippo Giorgio Di Girolamo

DOI: https://doi.org/10.3389/fcvm.2022.1028355

IF: 3.6

2022-10-28

Frontiers in Cardiovascular Medicine

Abstract:Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation via downregulation of ATP-citrate lyase and upregulation of AMP-activated protein kinase (AMPK). The primary effect is the reduction of cholesterol synthesis in the liver and its administration is generally not associated to unwanted muscle effects. Suppression of hepatic fatty acid synthesis leads to decreased triglycerides and, possibly, improved non-alcoholic fatty liver disease. Bempedoic acid may decrease gluconeogenesis leading to improved insulin sensitivity, glucose metabolism, and metabolic syndrome. The anti-inflammatory action of bempedoic acid is mainly achieved via activation of AMPK pathway in the immune cells, leading to decreased plasma levels of C-reactive protein. Effects of bempedoic acid on atherosclerotic cardiovascular disease, type 2 diabetes and chronic liver disease have been assessed in randomized clinical trials but require further confirmation. Safety clinical trials in phase III indicate that bempedoic acid administration is generally well-tolerated in combination with statins, ezetimibe, or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to achieve low-density lipoprotein cholesterol targets. The aim of this narrative review on bempedoic acid is to explore the underlying mechanisms of action and potential clinical targets, present existing evidence from clinical trials, and describe practical management of patients.

cardiac & cardiovascular systems
Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis

Muhammad Hamayal,Warda Shahid,Chaudhary Humayun Akhtar,Fnu Shekiba,Iqra Iftikhar,Muhammad Danyal Tahir,Muhammad Awwab,Saima Hussain,Saman Naeem,Momina Hafeez

DOI: https://doi.org/10.1080/14796678.2024.2388478

2024-08-14

Abstract:Aim: Statin intolerance and myopathy is a major issue with prolonged use of statins myopathy. Bempedoic acid can be a good alternative for those intolerant to statins. This systematic review aims to observe incidence of major adverse cardiovascular events (MACE) and other adverse events, in high-risk statin intolerant patients receiving bempedoic acid. Methods: Literature search was conducted via Google Scholar, Science Direct and PubMed, after which screening, selection and data extraction of articles was done. Meta-analysis was performed on RevMan 5.4. Subgroup analysis was also conducted and heterogeneity was evaluated. Risk of bias was performed using ROB2 assessment scale. (CRD42024536827). Results: Only six randomized controlled trials were used in final analysis consisting of 17,844 patients. Treatment with bempedoic acid was associated with a reduced risk of MACE compared with placebo (RR 0.86; 95% CI [0.79, 0.94] p = 0.0005), with myocardial infarction significantly reduced. Incidence of adverse effects was increased with bempedoic acid (RR: 1.02; 95% [1.00, 1.03] p = 0.01) but no significant difference was observed. Incidence of myalgia was reduced in bempedoic group as well. Conclusion: Bempedoic acid is a safe and effective alternative to statins in high-risk patients intolerant to statins, decreasing the risk of MACE.

Testosterone and human behavior: the role of individual and contextual variables.

Efficacy and Tolerability of Adding Coenzyme A 400 U/d Capsule to Stable Statin Therapy for the Treatment of Patients with Mixed Dyslipidemia: an 8-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study

Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update

Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs

Efficacy of Statin Monotherapy or in Combination with Coenzyme A Capsule in Patients with Metabolic Syndrome and Mixed Dyslipidemia

The proteins and the mechanisms of apoptosis: a mini-review of the fundamentals.

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials

Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials

Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Hybutimibe in Combination with Atorvastatin for Treatment of Hypercholesteremia among Patients with Atherosclerotic Cardiovascular Disease Risk Equivalent: A Multicenter, Randomized, Double-Blinded Phase III Study.

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia

Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review

A Systematic Review and Meta-Analysis on the Role of Bempedoic Acid in Cardiovascular Outcomes for Patients With Statin Intolerance

Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)

Combined brachytherapy and external radiotherapy for carcinoma of the prostate. Experience and results.

Chronic light damage to the macula of an endoscopist.

Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis

Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome

Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis